Biotech News

Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom

Pacira BioSciences (PCRX)Pacira BioSciencesCompany update

– Expands patient access to opioid-sparing pain control and advances 5x30 strategy – BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of

Related news

Pacira BioSciences

Non-Opioid Pain Management Pacira BioSciences develops and commercializes non-opioid therapies for postsurgical and musculoskeletal pain. Its portfolio combines extended-release pharmaceuticals, a cryoanalgesia device and a locally administered gene-therapy program. EXPAREL EXPAREL is a multivesicular-liposome formulation of bupivacaine...

Recent company news

Stock data

Close
25.01 USD
Market cap
875.49M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States